Brief: ThePI3K/AKT/mTOR pathwayis an intracellular signaling pathway important in regulating thecell cycle. Therefore, it is directly related to cellularquiescence,proliferation,cancer, and longevity. Phosphatidylinositol 3-kinase (PI3K), AKT, a serine/threonine protein kinase also known as protein kinase B (PKB), and mammalian target of rapamycin (mTOR) are 3 major nodes in the pathway. PI3Kactivationphosphorylatesand activatesAKT, localizing it in theplasma membrane.AKT can have a number of downstream effects such as activatingCREB,inhibitingp27,localizingFOXOin the cytoplasm,activatingPtdIns-3ps,and activatingmTORwhich can affect transcription of p70 or 4EBP1. mTOR is a component of the PI3K/AKT cell survival pathway that monitors the availability of nutrients, mitogenic signals and cellular energy and oxygen levels, a major regulator of the autophagic process, and alterations in components of the mTOR pathway have a major role in tumor progression. Therefore, mTOR is an appealing therapeutic target in many tumors. Encouraging data from preclinical studies have offered new opportunities to fully exploit the therapeutic potential of mTOR targeting in cancer.
The PI3K/Akt/mTOR Compound Library by SAB, containing 190 compounds targeting PI3K/Akt/mTOR signaling, can be used for high throughput screening and high content screening for new drugs.